Demand for biopharmaceuticals is growing, and bioseparation systems are advancing, hence it is anticipated that global market will see significant increase.

For patients with advanced and recurring ovarian cancer, Zejula appears to be the only poly (ADP-ribose) polymerase (PARP) agent having a licence in Singapore.

Exciting new research from AEGEAN shows that Imfinzi can boost lung cancer patient survival odds by inducing immune response both before and after surgery.

Lonza will implement ecologically appropriate building practises in order to reduce the amount of carbon dioxide emissions produced by the factory overall.